Highlights • The rapid test for antibodies to SARS-COV-2 was 90.1% sensitive and 100% specific • This is comparable to reference antibody tests for prior infection with COVID-19 • It could support clinical decision-making for patients with >10 days of symptoms • It would be useful in settings where vaccination is not widespread • And where PCR tests are not widely available Keywords COVID-19 rapid antibody test point-of-care lateral flow immunoassay sensitivity specificity Dear Editor, .
